Krka account plan
Generic pharmaceutical production and sales
At a glance
Krka is a Slovenian vertically integrated generic pharmaceutical group: 2025 revenue €2,041.0 million, 13,236 employees, sales in over 70 countries.
Krka, d. d., Novo mesto (founded 1954, listed on the Ljubljana Stock Exchange) is a vertically integrated generic pharmaceutical group that controls R&D, API and finished-product manufacturing, and marketing and sales through its own network. It sells prescription and non-prescription medicines, animal health products and health resort services to wholesalers, hospitals and pharmacies; over 100 million people use its products in over 70 countries, and markets outside Slovenia are 94% of sales. In 2025 revenue was €2,041.0 million (+7%), EBITDA €558.7 million (27.4% margin) and net profit €403.7 million (+13%). It had 13,236 employees at year-end 2025, 42% outside Slovenia, and has no non-current borrowings.
Business units
Prescription pharmaceuticals
83.2% of 2025 sales (€1,691.7 million)Medicines mainly for chronic diseases, with cardiovascular agents the largest class, plus central nervous system, gastrointestinal, pain relief and antidiabetic medicines. Sales rose 10% to €1,396.6 million in January–September 2026, led by the Russian Federation, Ukraine and Hungary.
Non-prescription products
8.5% of 2025 sales (€173.5 million)Cough and cold products, analgesics and vitamins under brands such as Septolete, Nalgesin, Herbion and Septanazal, sold mainly in central, eastern and south-eastern Europe. Sales fell 4% in January–September 2026 on a mild flu season.
Animal health products
5.6% of 2025 sales (€114.7 million)Mostly companion-animal products such as Milprazon, Fypryst and Selehold, plus farm-animal products. Sales rose 7% to €95.0 million in January–September 2026.
Health resort and tourist services (Terme Krka)
2.7% of 2025 sales (€54.2 million)Spas and hotels in Slovenia, including Terme Dolenjske Toplice, Terme Šmarješke Toplice, Hoteli Otočec and Talaso Strunjan, with 353,745 overnight stays in 2025.
Strategic priorities
- 2026–2030 growth and margin targets
- At least 5% average annual sales growth, an average EBITDA margin of at least 25% and at least 50% of net profit paid as dividends, with a top-5 generic position in all traditional markets.
- Single-pill combinations
- More than 200 combination medicines launched, over 30% of total sales; management credits product mix as the main driver of the margin gain.
- New therapeutic areas
- Entry into heart failure and obesity, plus complex formulations and peptide-based products; about 170 projects in development.
- R&D at 10% of revenue
- Allocate 10% of revenue to R&D, with more than 800 in-house experts; about 60% of R&D spend goes to new products and 40% to lifecycle management.
- Supply reliability and global capacity
- Treat supply reliability as a strategic asset and globalise capacity through joint ventures in India and China, with an average €150 million a year for capacity and infrastructure.
- Digitalisation and automation
- Accelerated digitalisation and automation, including artificial intelligence tools; an R&D digitalisation strategy for 2026–2030 was prepared.
Latest results
In January–September 2026 revenue rose 8% to €1,660.0 million, with 94% of sales outside Slovenia. Profitability grew faster: EBITDA rose 21% to €527.9 million (margin 31.8%), EBIT 24% to €455.5 million and net profit 13% to €364.2 million, as cost of goods sold stayed flat at €650.2 million. Region East Europe grew 14% to €606.7 million, led by the Russian Federation (+18%), while Region West Europe fell 2%. The 2026 estimate was raised to revenue of €2,179 million and net profit of €439 million, and the 2027 plan targets €2,308 million revenue and €474 million net profit.
Investments and deals
- India joint venture with Laurus Labs
- Krka holds 51% of Krka Pharma Private Limited in Hyderabad; completion is now targeted by the end of 2027, adding about 3 billion tablets a year of capacity.
- Slovenian plant upgrades
- Investments of €87.3 million in January–September 2026 (+31%): Notol and Notol 2 upgrades, a sterile solutions line extension, a high-bay warehouse at Ljutomer and veterinary capacity at Bršljin.
- Capex plan
- 2026 capex is now around €115 million because permits took longer; €141 million is planned for 2027.
- Share buybacks and dividends
- Dividend of €9.1 per share, the 27th consecutive increase; €31 million of buybacks in 9M 2026 and a new 3-year buyback programme for cancellation.
Challenges and risks
- Rouble exposure
- Foreign exchange risk is the only risk rated High: the long rouble position cannot be hedged with suitable instruments, and it produced a €9.7 million loss in 9M 2026.
- Price erosion and raw materials
- Management names price erosion, rising raw material prices, exchange rates and lower demand as risks to the plan.
- Weak West Europe
- Region West Europe sales fell 2% in 9M 2026, with declines in Italy, Spain, France, Belgium and the Netherlands.
- Supply chain and quality risks
- Supply of APIs and finished products, quality management, IT disruption and workforce availability are rated moderate risks.
What leadership says
“We are not only growing but growing more profitably.”
“Profitability remains a top priority. We don't chase sales at the cost of margins.”
“The Krka Group continues to be financially stable, is not dependent on debt financing, provides its shareholders with an attractive return, and maintains its independent path of development.”
Where a supplier can help
- Manufacturing automation and packaging
- Tied to the plant upgrades and digitalisation priority: robotic cells, packaging lines and automated warehouses are already being bought for Notol and Ljutomer.
- Capacity build-out in India
- Tied to the India joint venture: equipment, engineering and validation suppliers for a site adding about 3 billion tablets a year.
- Supply chain and quality systems
- Tied to the supply reliability priority and the supply and quality risks: planning, serialisation and quality-management tools across a multi-site network.
- R&D and regulatory digitalisation
- Tied to the R&D at 10% of revenue priority and the R&D digitalisation strategy: tools that speed development and the high volume of registration procedures.
- Sales force effectiveness
- Tied to the growth targets: Krka relies on more than 4,000 medical representatives, so CRM and field-force analytics support top-5 positions in its markets.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Krka?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Krka Group and Krka Annual Report 2025
- Krka (Novo mesto, Slovenia) is a vertically integrated generic pharmaceutical group: it controls R&D, API and finished-product manufacturing, marketing and sales; over 100 million people use its products in over 70 countries, and exports are 94% of sales.
- 2025 was a record year: revenue €2,041.0 million (+7%, first time above €2 billion), EBITDA €558.7 million (27.4% margin), EBIT €465.1 million, net profit €403.7 million (+13%), ROE 17.5%; product sales volume +5%.
- Prescription pharmaceuticals are 83.2% of sales (€1,691.7 million, +8%), non-prescription products 8.5% (€173.5 million), animal health 5.6% (€114.7 million), health resort and tourist services (Terme Krka) 2.7% (€54.2 million).
- Region East Europe is the largest region (€713.4 million, 35.1%); the Russian Federation is the largest single market (€422.3 million, +13%), followed by Poland (€230.1 million, +12%).
- 2026–2030 strategy: at least 5% average annual sales growth, at least 25% average EBITDA margin, 10% of revenue to R&D, €150 million average annual capex, at least 50% of net profit paid as dividends, top-5 generic company in all traditional markets.
- Combination (single-pill) medicines are the core innovation: over 150 in the portfolio; products launched in the last five years were 29% of sales; about 170 projects in development; new areas are heart failure and obesity, plus complex peptide-based products.
- Debt-free, with no non-current borrowings; foreign exchange risk (mainly the Russian rouble, which cannot be hedged with suitable instruments) is the only risk rated High.
- 2026 plan: €2.132 billion sales, €405 million net profit, investments of €141 million (over €140 million), headcount up 2% from 13,236; a joint venture plant with Laurus Labs in Hyderabad, India, is due to be completed by end-2026.
- January to September 2026 Unaudited Interim Report of the Krka Group and Krka
- Krka Group revenue for January–September 2026 was €1,660.0 million (+8%); 94% of product and service sales came from outside Slovenia.
- Profitability jumped: EBIT €455.5 million (+24%, margin 27.4%), EBITDA €527.9 million (+21%, margin 31.8%), net profit €364.2 million (+13%, margin 21.9%); cost of goods sold was flat at €650.2 million, 39.2% of revenue.
- Region East Europe grew 14% to €606.7 million (36.7% of sales), led by the Russian Federation (€372.1 million, +18%) and Ukraine (€82.7 million, +14%); Region West Europe fell 2% to €266.8 million.
- Prescription pharmaceuticals rose 10% to €1,396.6 million (84.5% of sales); non-prescription products fell 4% on a mild flu season; animal health rose 7%.
- Net financial result was −€4.4 million, including a €9.7 million foreign exchange loss on the long rouble position.
- 2026 estimate raised: revenue €2,179 million (+7%) and net profit €439 million (+9%, €34 million above plan); capex just under €115 million.
- 2027 plan: revenue €2,308 million (+6%), net profit €474 million (+8%), investments €141 million, headcount +2%.
- Investments were €87.3 million (+31%); ten new products were added; employees 13,307.
- Krka Group 1-9 2026 Business Performance Results Webcast (corrected transcript)
- David Bratož (Management Board member) presented record 9M 2026 results on 13 November 2026: revenue €1,660 million (+8%), operating profit €456 million (+24%), EBITDA €528 million (+21%), net profit €364 million (+13%).
- "We are not only growing but growing more profitably": gross margin reached 60.8%, EBITDA margin 31.8%; he attributes the margin gain mainly to product mix (single-pill combinations, new launches, reformulated products), with only a partial rouble effect.
- Single-pill combinations: more than 200 launched, over 30% of Krka's total sales, approaching 40% in some markets.
- Russia is the largest market (+18% in euros), with local production supplying more than 70% of products sold there; Krka has been present "for more than 50 years".
- R&D: up to 10% of sales, more than 800 in-house experts, over 170 products in the pipeline; about 60% of R&D for new products, 40% for lifecycle management.
- The India plant is targeted for completion by end-2027, adding about 3 billion tablets a year of capacity; capex guidance was cut to around €115 million for 2026 because permits took longer.
- Guidance raised: 2026 revenue €2,179 million and net profit €439 million; 2027 plan €2,308 million revenue and €474 million net profit, with capex €141 million.
- Dividend €9.1 per share (27th consecutive increase), €31 million of buybacks in 9M and a new 3-year buyback programme for cancellation.
- Krka Group FY 2025 Preliminary Business Performance Results Webcast (corrected transcript)
- David Bratož (Management Board member) presented FY2025 preliminary results and the 2026–2030 strategy on 29 January 2026: revenue above €2 billion for the first time (€2,041 million, +7%), EBITDA margin 27.4%, net profit up 13%.
- Russia was the top market at €422 million (+13%), with local production covering about 70% of sales; Poland grew 12% in value and 9% in volume; Ukraine flat at €96 million with 5% volume growth.
- The margin gain was driven "primarily by an improved product mix", partly supported by the rouble; net financial result €28 million.
- 2026 preliminary plan presented on the call: sales €2,144 million (+5%), net profit €405 million, capex €140 million.
- Strategy 2026–2030 is "not a revolution, it's rather an evolution": access to medicines, vertical integration, value creation; at least 5% growth and an EBITDA margin around 25%.
- Strategic updates: globalisation of capacities through joint ventures in India and China, supply reliability as a strategic asset, lifecycle management, entry into heart failure and obesity, and complex formulations and peptides.
- India JV with Laurus Labs (51/49) will add 3 billion tablets of capacity in its first phase; the China JV holds an EU GMP certificate.
- "We are a sales-driven company"; nearly 4,000 people in sales and marketing; "We don't chase sales at the cost of margins."
Questions about Krka
What does Krka do?
Krka develops, manufactures and sells generic prescription and non-prescription medicines and animal health products, and runs health resorts in Slovenia. It controls the chain from R&D and API production to its own sales network.
What is Krka's revenue?
2025 revenue was €2,041.0 million (+7%), the first time above €2 billion, with net profit of €403.7 million. The 2026 estimate is €2,179 million.
How many employees does Krka have?
13,307 employees at 30 September 2026, 42% of them outside Slovenia.
What is Krka's strategy?
The 2026–2030 strategy targets at least 5% annual growth and an EBITDA margin of at least 25%, built on combination medicines, new areas such as heart failure and obesity, and capacity in India and China.
Who leads Krka?
Jože Colarič has been President and CEO since 2005; the Management Board also includes Dr Aleš Rotar, Dr Vinko Zupančič and David Bratož.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)